DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial-Reference-Cited by-同舟云学术

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

Published:2019-09-30 Issue:11 Volume:129 Page:4769-4785
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Rouphael Nadine G.,Morgan Cecilia^ORCID,Li Shuying S.,Jensen Ryan^ORCID,Sanchez Brittany,Karuna Shelly,Swann Edith,Sobieszczyk Magdalena E.,Frank Ian,Wilson Gregory J.,Tieu Hong-Van,Maenza Janine,Norwood Aliza,Kobie James,Sinangil Faruk,Pantaleo Giuseppe,Ding Song^ORCID,McElrath M. Juliana,De Rosa Stephen C.,Montefiori David C.,Ferrari Guido,Tomaras Georgia D.^ORCID,Keefer Michael C.

Funder

NIH

Bill and Melinda Gates Foundation

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/128699/files/pdf

Reference42 articles.

1. [No authors listed]. HIV/AIDS fact sheet. World Health Organization. http://www.who.int/mediacentre/factsheets/fs360/en/ Updated July 19, 2018. Accessed August 21, 2019

2. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

3. Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

4. Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection

5. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses;Frontiers in Immunology;2024-06-06

2. Safety and immunogenicity of a DNA vaccine with subtype C gp120 protein adjuvanted with MF59® or AS01B: a phase 1/2a HIV-1 vaccine trial;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-05-03

3. DNA and protein HIV vaccines: how should we mix it?;The Lancet HIV;2024-05

4. Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial;The Lancet HIV;2024-05

5. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits;Nature Communications;2024-04-11